SCHEMBL24476410

SCHEMBL24476410

C#C[C@@]1(C(=O)OC)CCC2C3CCC4=CC(=O)CCC4C3CC[C@]21C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 5/20 0.69
▸ ABCB11 O95342 4/20 0.69
▸ LMNA P02545 4/20 0.69
▸ PGR P06401 4/20 0.69
▸ CYP2C19 P33261 3/20 0.69
▸ NR3C1 P04150 3/20 0.69
▸ SLC6A4 P31645 3/20 0.69
▸ SHBG P04278 3/20 0.69
▸ ESR1 P03372 2/20 0.69
▸ ALDH1A1 P00352 2/20 0.69
▸ TSHR P16473 1/20 0.69
▸ HIF1A Q16665 1/20 0.69
▸ ADRA2A P08913 1/20 0.69
▸ MEN1 O00255 3/20 0.68
▸ KMT2A Q03164 3/20 0.68
▸ AR P10275 3/20 0.68
▸ MAPT P10636 2/20 0.68
▸ CHRM2 P08172 1/20 0.68
▸ ADORA3 P0DMS8 1/20 0.68
▸ CHRM1 P11229 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24476298 0.91 CYP3A4 (0.73) CYP3A4ABCB11LMNAPGRCYP2C19
SCHEMBL10603264 0.90 CYP3A4 (0.72) CYP3A4ABCB11LMNAPGRCYP2C19
SCHEMBL24476245 0.85 AR (0.56) CYP3A4ABCB11LMNAPGRCYP2C19
Norethindrone SCHEMBL24476231 0.82 CYP3A4 (1.00) CYP3A4ABCB11LMNAPGRCYP2C19
Norethindrone SCHEMBL14074493 0.82 CYP3A4 (1.00) CYP3A4ABCB11LMNAPGRCYP2C19
Norethindrone SCHEMBL7768886 0.82 CYP3A4 (1.00) CYP3A4ABCB11LMNAPGRCYP2C19
Norethindrone SCHEMBL14577661 0.82 CYP3A4 (1.00) CYP3A4ABCB11LMNAPGRCYP2C19
Norethindrone SCHEMBL6834811 0.82 CYP3A4 (1.00) CYP3A4ABCB11LMNAPGRCYP2C19
Norethindrone SCHEMBL23390 0.82 CYP3A4 (1.00) CYP3A4ABCB11LMNAPGRCYP2C19
Norethindrone SCHEMBL19510084 0.82 CYP3A4 (1.00) CYP3A4ABCB11LMNAPGRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220169672-A1 COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER PURDUE RESEARCH FOUNDATION 2022-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169672-A1 COMPOUNDS FOR TARGETED THERAPIES OF CASTRATION RESISTANT PROSTATE CANCER KLK3, AR, ACP3 CYP3A4 3616/4885ABCB11 2232/4885LMNA 4233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback